Market Overview
Diffuse Large B-cell Lymphoma Therapeutics Market size was valued at USD 4,107.50 million in 2021 and is estimated to reach at a compound annual growth rate (CAGR) of 7.50% over the forecast period 2022 to 2029. Lymphoma is cancer affecting the immune system’s lymphatic system. Lymphoma develops when lymphocytes divide uncontrollably. B lymphocytes cause large lymphomas. Thus, huge diffuse B-cells are formed from large and aberrant B cells, which are different types of the normal B cell. DLBCL (diffuse large B cell lymphoma) is a frequent type of non-Hodgkin’s lymphoma (NHL) that is the fastest developing and affects B cells. These B-cell lymphocytes aid in the fight against infections and the healthy operation of the lymphatic system. DLBCL can also develop in extranodal locations such as the thyroid, skin, gastrointestinal system, bone, breast, and others. Men are more likely to be affected than women. Furthermore, this type of lymphoma comprises increased B cells and cancer cells that spread the pattern.
The Diffuse Large B-cell Lymphoma Therapeutics Market study analysis offers an in-depth outlook on the market containing both quantitative, and qualitative data. It gives an outlook and forecast of the global market based on the Diffuse Large B-cell Lymphoma Therapeutics Market segmentation by drug type, and end user. It also provides Diffuse Large B-cell Lymphoma Therapeutics Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global Diffuse Large B-cell Lymphoma Therapeutics Market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.
The global diffuse large b-cell lymphoma therapeutics market growth is driven by the increasing incidence of DLBCL (Diffuse Large B-Cell Lymphoma), increasing preference for targeted therapies, and technological advancement coupled with advanced drug therapeutics.
Increasing preference for targeted therapies is expected to drive market growth in the forecast period.
Targeted therapy is one of the most widely preferred methods for treating diffuse large B-cell lymphoma, as targeted therapy is less toxic to healthy cells than chemotherapy. Targeted therapies act on specific molecular targets that are associated with cancer. Monoclonal antibodies, kinase inhibitors, immunomodulatory drugs, and nuclear export inhibitors are the targeted therapies for NHL. Rituximab is a targeted therapy that is used to treat a variety of B-cell NHL types. It works by focusing on a molecule known as CD20, which is found on the surface of both normal B cells and B-cell NHL cells. Ibrutinib is a targeted therapy that inhibits Bruton’s tyrosine kinase pathway. Moreover, mantle cell lymphoma, marginal zone lymphoma, small lymphocytic lymphoma, chronic lymphocytic leukemia, and Waldenstrom macroglobulinemia are among the B-cell lymphomas for which it has been approved.
Recent progress in molecular biology has led to a better understanding of the oncogenic drivers of DLBCL, resulting in the development of many targeted therapies undergoing evaluation in phase I and II trials. Ibrutinib (Imbruvica), a targeted therapy approved by the FDA for use in multiple forms of lymphoma, has been tested in DLBCL to investigate if it affects the subtypes differently.
The high cost of treatment is expected to hamper the market growth.
The high cost associated with the treatment of diffuse large B-cell lymphoma is expected to restrain the market’s growth to a certain extent, as it limits the number of individuals undergoing the treatment. Moreover, according to the National Library of Medicine, in 2022, the economic burden of DLBCL will be high. The average DLBCL-related cost per patient per year in the first year of treatment was reported to be significantly higher for second-line (2L) DLBCL patients (210,488 US dollars (USD)) compared to first-line (1L) patients (25,044 USD) in the US. Other costs considered were adverse events, treatment administration and monitoring, disease management, and future healthcare costs. For instance, they discovered that lifetime costs could vary from $600,000 to $750,000, with the cost of adverse events related to third-line treatment representing 30% of the total cost. Treatment acquisition (28%) and subsequent therapy (21%) are the other costs. The lifetime cost of treating RR DLBCL can surpass $1 million after including the cost of first- and second-line therapies.
Industry Analysis
The diffuse large b-cell lymphoma therapeutics market provides in-depth analysis of the market based on various industry factors such as porter five forces, unmet needs, pricing analysis, supply chain analysis, regulatory analysis etc.
Segmentation Analysis
The immune and targeted drugs segment is expected to hold the largest share in diffuse large b-cell lymphoma therapeutics market.
Targeted therapeutics is a type of cancer treatment that uses drugs to target cancer cells without affecting normal cells. Although targeted therapy is effective, many individuals prefer to use it with other therapies, such as traditional or standard chemotherapy, surgery, or radiation therapy. Developments in research for DNA changes and proteins that drive cancer are proving effective in designing promising treatments that target such proteins. For different types of cancers come different types of drugs that individually target distinct cancer. However, tumors are tested to check the target and provide therapy if the drugs are available. As traditional chemotherapy can damage normal cells while killing cancer cells, the targeted therapeutics segment is expected to witness growth during the forecast period. The targeted cancer therapies market is growing due to the increasing incidence of diffuse large b-cell lymphoma (DLBCL). For instance, as per the lymphoma organization, diffuse large b-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in the United States, accounting for about 22 percent of newly diagnosed cases of B-cell NHL in the United States. More than 18,000 people are diagnosed with DLBCL each year.
Robust R&D studies are underway to develop new drugs and therapies for DLBCLs. Several products from different companies are in different phases of clinical trials and will be available in the market during the forecast period. For instance, Roche’s Glofitamab (Anti-CD20 CD3 TCB, RG6026) is a T cell-engaging bispecific antibody designed to engage both CD20 on B cells and CD3 on T cells. By engaging both targets simultaneously, the antibody activates the T cells to attack and eliminate the B cells, allowing treatment of B cell cancers such as non-Hodgkin’s lymphoma, which is under Phase 1 clinical trials and is expected to be completed by the end of 2022. ?

COVID-19 Impact Analysis
The COVID-19 pandemic continues to endanger global health and hinder the world economy. It has been widely observed that patients with existing diffuse large b-cell lymphoma experience higher complications due to COVID-19. The degree to which ongoing chemotherapy impacts the outcome of patients with COVID-19 remains controversial. Still, at least one large study shows that individuals with diffuse large b-cell lymphoma undergoing treatment when diagnosed with COVID-19 are at high risk of severe complications. There is also data suggesting that patients with lymphoma are more susceptible to infection with SARS-CoV-2. According to one report, the more intense the therapy, the greater the impact on clinical outcomes in patients who contract COVID-19. The high morbidity and mortality rates reported in patients with hematologic malignancies underscore the vulnerability of this patient population.
Most facilities check patients who begin therapy in an outpatient clinic or monthly or are admitted to the hospital for treatment. Depending on the frequency of COVID-19 and the availability of screening, practices vary. Individualized decisions on when and how to treat a good result are required. Patients with diffuse large B-cell lymphoma undergoing treatment with an anti-CD20 antibody have an impaired response to the BNT162b2 mRNA (by Pfizer-BioNTech) COVID-19 vaccine, according to research published in Blood Advances. Patients who had any exposure to anti-CD20 therapy were less likely to have a response to the COVID-19 vaccine. Patients with an absolute lymphocyte count were also less likely to respond to the vaccine. This will create problems for patients who are presently taking therapies.

Geographical Analysis
North America holds the largest market share of the global diffuse large b-cell lymphoma therapeutics market.
North America dominates the market owing to factors such as the increasing prevalence of diffuse large b-cell lymphoma (DLBCL) cases and rising healthcare awareness among the population. As per the lymphoma organization, diffuse large b-cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma (NHL) in the United States, accounting for about 22 percent of newly diagnosed cases of B-cell NHL in the United States. More than 18,000 people are diagnosed with DLBCL each year. The estimates are expected to increase due to the rising trend in Non-Hodgkin’s Lymphoma (NHL) incidence and DLBCL incidence in the region, combined with underlying demographic changes. It is a mature B-cell neoplasm emanating from the germinal center and post-germinal center B-cells.
Furthermore, the increasing focus of manufacturers on the adoption of inorganic growth strategies, such as partnerships and acquisitions, to strengthen their product portfolio of relapsed or refractory diffuse large B-cell lymphoma is anticipated to drive market growth in the region. For instance, the FDA recently authorized Monjuvi(R) (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL).

Competitive Landscape
Major key players in the diffuse large b-cell lymphoma therapeutics market are Hoffmann-La Roche Ltd, Novartis AG, Celltrion, Karyopharm Therapeutics, Kite Pharma, MorphoSys AG, AbbVie, CTI BioPharma, Seagen Inc., TG Therapeutics among others.
F. Hoffmann-La Roche Ltd:

Overview:
Roche was founded in 1896 in Basel, Switzerland. It creates innovative medicines and diagnostic tests that help millions of patients globally. Roche was one of the first companies to bring targeted treatments to patients. With their combined strength in pharmaceuticals and diagnostics, they are better equipped than any other company to drive personalized healthcare further. Two-thirds of their research and development projects are being developed with companion diagnostics. In March of 2009, Genentech became a member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
?Product Portfolio:
The company portfolio includes Rituxan (rituximab)/MabThera were the first therapeutic monoclonal antibody to target cells that have the CD20 marker on their surface. These cells are central to many blood cancers, including common forms of lymphoma and leukemia.
The global diffuse large b-cell lymphoma therapeutics market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.